Delving into the Latest Updates on Clopidogrel Bisulfate with Synapse

Overview

Basic Info

SummaryClopidogrel Bisulfate, a medication trademarked as Plavix®, was approved by Bristol Myers Squibb in the US in 1997. Its mechanism of action is to inhibit P2Y12 receptors, which reduces platelet activation and aggregation. This subsequently decreases the risk of blood clots and their potentially fatal consequences. Clopidogrel is indicated for treating myocardial infarction, stroke, peripheral vascular disease, coronary artery disease, and cerebrovascular disease. With its role as an antiplatelet agent, Clopidogrel proves invaluable in preventing severe complications from blood clots such as heart attacks, strokes, and even death. The drug has shown efficacy in the management and prevention of cardiovascular events, making it an essential medication in modern medicine.

Drug Type

Small molecule drug

Synonyms

clopidogrel, Clopidogrel Bisufate, Clopidogrel bisulfate (USP)

+ [33]

Target

P2Y12 receptor

Action

antagonists

Mechanism

P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesOther Diseases

Active Indication

AtherosclerosisIschemiaAngina, Stable+ [15]

Inactive Indication

Acute myocardial infarctionChronic heart failureHeart Defects, Congenital+ [3]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

KRKA ddHCS bvba

Viatris, Inc.

+ [10]

Inactive Organization

Bristol Myers Squibb Co.Norpharm Regulatory Services Ltd.

Acino AG

+ [7]

License Organization

Bristol Myers Squibb Co.

Ascendia Pharmaceuticals, Inc.Sanofi-Aventis Korea Co., Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (17 Nov 1997),

Myocardial InfarctionStroke

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC16H18ClNO6S2

InChIKeyFDEODCTUSIWGLK-RSAXXLAASA-N

CAS Registry120202-66-6

The primary aim of this study is to investigate the PD effects of switching from standard-dose clopidogrel dose to low-dose prasugrel versus continuing standard-dose clopidogrel in patients at dual-risk (HBR defined as the HBR-ARC criteria and HIR defined as ABCD-GENE score ≥10) following PCI. We hypothesize that in patients at dual-risk, switching from standard-dose clopidogrel to low-dose prasugrel will be superior to continuing standard-dose clopidogrel in terms of platelet reactivity.

Start Date15 Sep 2025

Sponsor / Collaborator

University of Florida

NCT07012629

/ Not yet recruitingPhase 3IIT

A EUROpean Pragmatic Multicenter Randomized Trial on Platelet Inhibition and/or Lipid Lowering Treatment in Covert Brain Infarction (CBI)

Magnetic resonance imaging (MRI) is commonly used in healthcare, and sometimes it shows small areas of brain damage called Covert Brain Infarcts (CBIs). These are usually found by chance when people have scans for things like headaches or dizziness. Although CBIs don't cause symptoms at the time, they are linked to a higher risk of future stroke and death.
There is currently no standard treatment for CBIs, and doctors have different approaches-some give stroke-preventing medication (like antiplatelets or statins), while others don't treat at all. This is mostly because there isn't enough research yet.
This study will test whether stroke-preventing treatments help people with CBIs. It will also look at whether having a CBI increases the risk of dementia, and whether treatment might lower that risk.

Start Date01 Sep 2025

Sponsor / Collaborator

Århus Universitetshospital

[+8]

NCT07076082

/ Not yet recruitingPhase 4IIT

Vascular Trial Associated Registry Pilot: Antiplatelet Therapies for Patients Undergoing Lower Extremity Endovascular Revascularization

The purpose of this investigator-initiated, multicenter, open label, randomized trial is to evaluate 1 month vs. 6 months of dual antiplatelet therapy (DAPT) in patients undergoing lower extremity endovascular revascularization. We hypothesize that extending dual antiplatelet therapy (DAPT) to six months, compared to one month, will improve patency rates of target vessels following peripheral vascular intervention (PVI) without significantly increasing complications, particularly bleeding events.

Start Date30 Aug 2025

Sponsor / Collaborator

Spectrum Health Hospitals, Inc.

[+1]

100 Clinical Results associated with Clopidogrel Bisulfate

Login to view more data

100 Translational Medicine associated with Clopidogrel Bisulfate

Login to view more data

100 Patents (Medical) associated with Clopidogrel Bisulfate

Login to view more data

9,518

Literatures (Medical) associated with Clopidogrel Bisulfate

01 Nov 2025·ANNALS OF VASCULAR SURGERY

Retrograde Femoral Access Flipped Antegrade Technique and its Effect on Patient Outcomes Following Lower Extremity Angiography

Article

Author: Kronick, Matthew D ; Hadro, Neal ; Strecker, Zachary ; Lin, Alex M ; Marecki, Hazel ; Norris, Marc

BACKGROUND:

Common femoral artery access is a critical step in the endovascular treatment of peripheral artery disease. Traditionally, access is obtained either by a retrograde approach from the contralateral leg with an "up-and-over" aortic bifurcation technique, or in an antegrade fashion in the ipsilateral leg. Retrograde arterial access flipped antegrade in the ipsilateral femoral artery incorporates the technical ease of retrograde access (RA) with mechanical advantages of antegrade access (AA). There are limited studies directly comparing these techniques. The objective of this study is to describe and compare the different techniques for accessing the common femoral artery for diagnostic and therapeutic endovascular infrainguinal interventions.

METHODS:

This is a retrospective cohort study of patients undergoing lower extremity diagnostic and therapeutic angiography through either contralateral retrograde (RA), ipsilateral antegrade (AA), or retrograde femoral access flipped antegrade (RAFA) between October 1st, 2018, and September 30th, 2020. Outcomes measured were technical success, complications including hematoma, hemorrhage requiring transfusion, pseudoaneurysm, and repeat operative intervention. Differences in patient and treatment characteristics were analyzed using 2-sample t-test, Fisher's exact test and Chi-squared test. Multivariable logistic regression analysis was performed to identify associations with different access techniques and study outcomes.

RESULTS:

Of the 342 lower extremity endovascular procedures, 156 (45.6%) used RA access, 82 (24.0%) AA access, and 104 (30.4%) RAFA access. There were no significant differences in the mean age, gender, and body mass index between patients undergoing different access method cohorts (P > 0.05). The RAFA cohort had a significantly higher percentage of patients taking Plavix (46%) than retrograde (24%) and antegrade (34%) patients (P < 0.001). Patients undergoing RAFA access were less commonly active smokers (P = 0.003) or had chronic obstructive pulmonary disease (P = 0.001). Fluoroscopic confirmation of arterial puncture occurred less frequently in the AA cohort (P = 0.037). Technical success rate during therapeutic intervention was highest in the AA cohort (RA, 84%; AA, 98%; RAFA, 91%; P = 0.024). The AA cohort had the highest overall complication rate (RA, 10%; AA, 23% RAFA, 8.0%; P = 0.025) and the highest rate of requiring return to odds ratio (RA, 4.7%; AA, 17%; RAFA, 4.5%; P = 0.021). There were no significant differences in the incidence of hematoma, pseudoaneurysm, or death between all 3 cohorts (P > 0.05).

CONCLUSION:

The use of a RAFA technique for infrainguinal diagnostic and therapeutic endovascular therapy is not well studied. Our study demonstrates that this technique had a high rate of technical success without increasing the risk for access site complications compared to the traditional femoral artery access.

01 Oct 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Effect of extracorporeal circulation on structure of main components of animal plasma – ATR-IR and 2D-COS studies. Part II: Presence of antithrombotic drugs

Article

Author: Czarnecki, M A ; Olsztyńska-Janus, S

An application of extracorporeal circulation (ECC) requires using antithrombotic drugs to maintain blood fluidity and prevent thrombotic complications. The molecular mechanism of this process is not fully elucidated; therefore, we undertook an examination of the effect of antithrombotic drugs (aspirin and clopidogrel) on changes in the structure of the main plasma components during ECC. The spectral variations were monitored using ATR-IR (Attenuated Total Reflection Infrared) spectroscopy and analyzed by moving-window approach and two-dimensional correlation spectroscopy (2D-COS). For samples subjected to anticoagulant therapy, we observed a much higher extent of spectral changes, as compared with the control samples. The most significant changes were observed for the bands from water and amide moieties. The obtained results demonstrate high sensitivity and reliability of ATR-IR spectroscopy coupled with advanced numerical analysis for monitoring variations in the structure and composition of blood plasma during ECC.

01 Sep 2025·TALANTA

Simultaneous enantiomeric separation of linagliptin and clopidogrel by capillary electrophoresis for the individual, combined, and enantiomeric ecotoxicity evaluation on Pseudokirchneriella subcapitata

Article

Author: Marina, María Luisa ; García, María Ángeles ; Boltes, Karina ; García-Cansino, Laura

An analytical methodology was developed in this work enabling the simultaneous enantioseparation of linagliptin and clopidogrel by Capillary Electrophoresis (CE). The use of 10.4 mg/mL carboxymethyl-β-CD (CM-β-CD) as chiral selector in 25 mM phosphate buffer (pH 7.0), at 25 °C and a separation voltage of 30 kV, made possible the chiral separation in 7.4 min, with resolution values of 3.9 and 2.7 for linagliptin and clopidogrel enantiomers, respectively. The analytical characteristics of the developed methodology were evaluated in terms of linearity, precision, trueness, LODs and LOQs, and found adequate for the enantiomeric determination of both drugs. The method was applied to study the stability under abiotic and biotic conditions and the ecotoxicity of both drugs on Pseudokirchneriella subcapitata at individual, combined, and enantiomeric level. Both studies were carried out for each enantiomer of linagliptin, racemic linagliptin, S-clopidogrel, racemic clopidogrel, a mixture of the active enantiomers (R-linagliptin and S-clopidogrel), and a mixture of both racemates. Results obtained showed that individual solutions of S-linagliptin, R-linagliptin, S-clopidogrel, RS-linagliptin, and a mixture of the active enantiomers of both compounds, were stable under abiotic and biotic conditions, regardless of the incubation time; however, the concentration of racemic clopidogrel after 96 h of incubation showed a decay which ranged from 18 to 24 % under abiotic and biotic conditions, respectively. Experimental determination of ecotoxicological parameters demonstrated that all compounds studied (individual enantiomers, racemates, the combination of active enantiomers, and racemic mixtures) are highly toxic to algae. In mixtures, different degrees of antagonisms and synergism were observed.

165

News (Medical) associated with Clopidogrel Bisulfate

01 Jul 2025

·www.prnewswire.com

Gene by Gene Supports Landmark Pharmacogenomics Trial to Personalize Prescribing in NHS Scotland

PHOENIX Study harnesses Gene by Gene's accredited lab testing to optimize treatment for thousands of patients across Greater Glasgow and Clyde HOUSTON and GLASGOW, Scotland, July 1, 2025 /PRNewswire/ -- A major new study launching in Scotland aims to show how a simple genetic test could help doctors personalise treatments – boosting medication response and reducing harmful side effects. The PHOENIX Study, one of the largest trials of its kind in the world, will recruit up to 4,000 patients over the next two years in the NHS Greater Glasgow and Clyde area to investigate how an individual's genetic profile affects their response to 60 commonly prescribed medications. Researchers hope the trial will pave the way for more tailored prescribing across the NHS. Led by Sandosh Padmanabhan, Pontecorvo Chair of Pharmacogenomics at the University of Glasgow, the PHOENIX Study will take place at the Queen Elizabeth University Hospital (QEUH) in Glasgow in partnership with the University of Glasgow's Living Laboratory, the NHSGGC-hosted West of Scotland Innovation Hub, and industry partners myDNA and Agena Bioscience. Recruitment for the trial began this Spring and focuses on patients who are newly prescribed one or more of the 60 widely used medications in the NHS. With consent, participants will undergo a simple genetic test to analyse their DNA. The results – returned within days – will help doctors determine whether each patient is receiving the most suitable drug and dosage based on their genetic makeup. Around 15% of patients are expected to carry genetic variants that may reduce the effectiveness of a medication or increase the risk of side effects. In some cases, the prescribed drug may be ineffective; in others, a different dosage may be needed. Without prior genetic testing, these issues can go unnoticed, often leading to a trial-and-error approach to treatment. Pharmacogenomics (PGx) – the study of how genes influence individual responses to drugs – offers a way to personalise prescribing and improve outcomes. Yet this approach has not been routinely used in clinical practice in the UK. The PHOENIX Study seeks to provide the real-world evidence needed to change that. Patients in the study will have a range of health conditions and be treated in different specialties across the hospital, including cardiology, stroke, surgery, general medicine, orthopaedics, geriatrics, gynaecology, ENT, rheumatology, respiratory, neurology, psychiatry and other specialities. The trial is open to adult in-patients of all ages in the QEUH. Patients enrolled on the PHOENIX trial will be randomly assigned to either receive the pharmacogenomic test immediately or at three months, which will allow the researchers to establish evidence of benefit. The genetic test results will be sent to clinicians managing each patient's care, allowing for treatment decisions to be adjusted. Patients will be followed up regularly to monitor the effects of any changes, helping ensure they continue to receive the highest standard of care. Eric Balish is one of the first patients to be enrolled into the PHOENIX Study. He was asked to take part in the trial by consultants at the Queen Elizabeth University Hospital in Glasgow, after having a heart attack. Eric was immediately prescribed clopidogrel, one of the 60 drugs included in the study, but has since had his medication changed several times. Now, just over a month after surgery, Eric is recovering. Like all patients on the trial, he doesn't know which arm of the study he has been assigned to, but he feels positive about the information taking part might bring for himself and others. (Please find a selection of images of Eric and the trial leads here: ) He said: "I knew a bit about personalised medicine previously, and so when I was asked to take part in the PHOENIX Study I was happy to do it. If you're asked to participate and support long-term research like this, then it's no great hardship to give something back and just do the right thing. I am hopeful my information can be of use to the trial and in the future." Professor Sandosh Padmanabhan, who is also a consultant at the QEUH, said: "Physicians and pharmacists increasingly recognise that PGx-informed prescribing and dispensing improves both the efficacy and safety of drug treatment. "The primary goal of this trial is to evaluate the clinical and health-economic impact of PGx-guided prescribing. "Specifically, we want to determine if a PGx-guided approach to prescribing can significantly reduce the incidence and severity of drug related side effects and/or treatment failures. This evaluation will compare the outcomes of participants who receive PGx-guided medication management to those receiving standard care." Dr Katriona Brooksbank, Research and Innovation Lead for NHSGGC and the West of Scotland Innovation Hub, said: "We are incredibly excited to be supporting this trial, which could have a major impact on the treatments patients are prescribed based on their own genetics. "It will put precision medicine into action as researchers look to determine how a person's own genetic make-up can affect the drugs they are given as treatments. This could allow clinicians to reduce adverse reactions and side effects, ensuring the best possible outcomes for patients." If successful, the PHOENIX Study could lead to wider implementation of genetic testing in prescribing across Scotland, making precision medicine a routine part of healthcare. Allan Sheffield, Director of Gene by Gene and myDNA, said: "For myDNA, the PHOENIX Study embodies the future of healthcare. Our unique combination of pharmacogenomic clinical decision support and in-house Gene by Gene accredited testing empowers clinicians to move beyond guesswork. This trial will demonstrate the profound impact of precision medicine, paving the way for a future where this approach routinely drives better patient outcomes." Gene by Gene is a world leader in genetic testing services with over 20 years of experience. Our laboratory holds accreditation from multiple agencies, including CAP, CLIA, New York State Department of Health, California Department of Public Health, and AABB. With a cutting-edge laboratory and highly trained team of experts, we are committed to excellence in the field of genetic analysis. To learn more about Gene by Gene, visit . Media contact: Andrew Thompson-Young For Gene by Gene [email protected] SOURCE Gene by Gene WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Study

06 Jun 2025

·pharma.economictimes.indiatimes.com

Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients

London: Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50 per cent reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting. Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15 per cent of colon cancer patients have dMMR tumors , which do not respond well to chemotherapy. "The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement. The data were presented at the ASCO meeting that concluded earlier this week. The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months. The other half of the patients received chemotherapy for 12 months. The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said. ASPIRIN MAY NOT BE BEST LONG-TERM OPTION AFTER HEART PROCEDURE As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests. Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use. But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ. Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI. After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding. That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy. Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin "due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term," according to an editorial published with the study. But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed. LONG-TERM GLP-1 USE LINKED TO HIGHER RISK OF AGE-RELATED EYE DISEASE Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology. In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness. The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users. Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use. Semaglutide is the active ingredient in the widely used Novo Nordisk drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's discontinued Adlyxin. GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect. At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD. "Our findings are not directly contradictory" with that earlier report, said study leader Dr. Reut Shor of the University of Toronto. "Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends." (To receive the full newsletter in your inbox for free sign up here) (Reporting by Nancy Lapid; additional reporting by Shawana Alleyne-Morris; editing by Bill Berkrot)

Clinical ResultImmunotherapyClinical Study

12 May 2025

·www.biospace.com

BMS, Sanofi Settle Plavix Suit With Hawaii for $700M

iStock, beast01 The Plavix lawsuit dates back to 2014, when Hawaii first sued BMS and Sanofi, alleging that they failed to properly inform patients in the state that the drug is likely to be less effective for them. The state of Hawaii on Friday settled its long-standing legal dispute with Bristol Myers Squibb and Sanofi over the companies’ blood thinner Plavix. Each company will hand over $350 million by June 9 to satisfy the settlement, though neither accepted any liability in connection with the state’s allegations, as per the agreement. The payment will release BMS and Sanofi from “any and all claims of any kind . . . in any way related to the State’s claim” against the companies. The settlement, however, does not prevent private citizens from Hawaii from bringing their own claims against BMS and Sanofi. Friday’s agreement ends more than a decade of litigation over Plavix , an oral blood thinner initially approved in 1997 and indicated for acute coronary syndrome and to reduce the risk of heart attacks and strokes in patients who have had recent cardiovascular episodes. The drug comes with a boxed warning, flagging that Plavix’ effectiveness “depends on [its] conversion to an active metabolite by” a certain enzyme. In 2014, the state of Hawaii sued BMS and Sanofi, alleging that the companies engaged in deceptive marketing practices by not informing patients in Hawaii that certain population-specific factors there make Plavix not only less effective but also potentially more harmful . In May 2024, First Circuit Court Judge James Ashford awarded Hawaii a more-than $900 million victory against BMS and Sanofi, finding that the companies indeed knew “that there was a risk that about thirty percent of patients might have diminished response to Plavix” but nevertheless decided against updating the drug’s label, as per a news release from the state at the time. Before an appeal of the $900 million payment could be completed, the state and the companies settled at the lower amount of $700 million. The companies, according to Ashford, engaged in “unfair acts or practices,” which he deemed were “deliberate and pervasive.” The lack of upfront information about the efficacy of Plavix “raises a serious risk of harm to all consumers, but a particularly high risk to patients of East Asian and Pacific Islander descent, who represent a significant portion of Hawaii’s population.” While BMS and Sanofi have entered a settlement agreement over Plavix, fellow Big Pharma J&J early last month announced that it would abandon its proposed $7 billion settlement plan for its talc lawsuits and instead “return to the tort system to litigate and defeat these meritless talc claims.” This decision comes after the Bankruptcy Court in Houston rejected the pharma’s proposal, which would have closed thousands of cases, alleging that its talc baby powder caused cancer.

Drug ApprovalPatent Infringement

100 Deals associated with Clopidogrel Bisulfate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00769	Clopidogrel Bisulfate	B01AC04	DB00758

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Atherosclerosis	Australia	Sanofi-Aventis Australia Pty Ltd.	06 Jul 2001
Ischemia	Australia	Sanofi-Aventis Australia Pty Ltd.	06 Jul 2001
Angina, Stable	China	Shenzhen Salubris Pharmaceuticals Co., Ltd.	01 Jan 2000
Cerebrovascular Disorders	China	Shenzhen Salubris Pharmaceuticals Co., Ltd.	01 Jan 2000
Myocardial Ischemia	China	Shenzhen Salubris Pharmaceuticals Co., Ltd.	01 Jan 2000
Non-St Elevated Myocardial Infarction	China	Shenzhen Salubris Pharmaceuticals Co., Ltd.	01 Jan 2000
Non ST segment elevation acute coronary syndrome	European Union	Sanofi Winthrop Industrie SA	15 Jul 1998
Non ST segment elevation acute coronary syndrome	Iceland	Sanofi Winthrop Industrie SA	15 Jul 1998
Non ST segment elevation acute coronary syndrome	Liechtenstein	Sanofi Winthrop Industrie SA	15 Jul 1998
Non ST segment elevation acute coronary syndrome	Norway	Sanofi Winthrop Industrie SA	15 Jul 1998
Non-Q wave myocardial infarction	European Union	Sanofi Winthrop Industrie SA	15 Jul 1998
Non-Q wave myocardial infarction	Iceland	Sanofi Winthrop Industrie SA	15 Jul 1998
Non-Q wave myocardial infarction	Liechtenstein	Sanofi Winthrop Industrie SA	15 Jul 1998
Non-Q wave myocardial infarction	Norway	Sanofi Winthrop Industrie SA	15 Jul 1998
ST Elevation Myocardial Infarction	European Union	Sanofi Winthrop Industrie SA	15 Jul 1998
ST Elevation Myocardial Infarction	Iceland	Sanofi Winthrop Industrie SA	15 Jul 1998
ST Elevation Myocardial Infarction	Liechtenstein	Sanofi Winthrop Industrie SA	15 Jul 1998
ST Elevation Myocardial Infarction	Norway	Sanofi Winthrop Industrie SA	15 Jul 1998
Acute Coronary Syndrome	European Union	Sanofi Winthrop Industrie SA	14 Jul 1998
Acute Coronary Syndrome	Iceland	Sanofi Winthrop Industrie SA	14 Jul 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Old myocardial infarction	Phase 3	Japan	Sanofi	01 Dec 2008
Heart Defects, Congenital	Phase 3	United States	Sanofi	01 Nov 2006
Heart Defects, Congenital	Phase 3	China	Sanofi	01 Nov 2006
Heart Defects, Congenital	Phase 3	Argentina	Sanofi	01 Nov 2006
Heart Defects, Congenital	Phase 3	Belgium	Sanofi	01 Nov 2006
Heart Defects, Congenital	Phase 3	Brazil	Sanofi	01 Nov 2006
Heart Defects, Congenital	Phase 3	Canada	Sanofi	01 Nov 2006
Heart Defects, Congenital	Phase 3	Denmark	Sanofi	01 Nov 2006
Heart Defects, Congenital	Phase 3	Egypt	Sanofi	01 Nov 2006
Heart Defects, Congenital	Phase 3	Finland	Sanofi	01 Nov 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04824911 (Statin and Dual Antiplatelet Therapy in Preventing Early Neurological Deterioration in Branch Atheromatous Disease, Pubmed \| Ther Adv Neurol Disord)	Phase 2	Plaque, Atherosclerotic	376	Aspirin, clopidogrel, and high-intensity statins	dnyuiazldm(nwdmfrvcjx) = lgstcsqggn fuaishkofl (pkeivpsexp ) View more	Positive	01 Jan 2025
				Single antiplatelet therapy and moderate- or low-intensity statins	dnyuiazldm(nwdmfrvcjx) = gugxcazfac fuaishkofl (pkeivpsexp ) View more
NCT02777580 (STREAM-2, CTgov)	Phase 4	Myocardial Infarction \| ST Elevation Myocardial Infarction	609	Coronary angiography+Clopidogrel+Tenecteplase (Pharmaco-invasive Strategy)	kzneyjsxth = cbuuevfyoz ryjfdzoitm (gkaaiqejvc, atwylpcbij - dctzoionvw) View more	-	04 Oct 2024
				Primary PCI (Standard Primary PCI)	kzneyjsxth = evqswctmut ryjfdzoitm (gkaaiqejvc, xaevslrnyr - rfqqblknjm) View more
FAST-MI 2015 (ESC2024)	Not Applicable	Acute myocardial infarction	-	Ticagrelor	wkvhocwhtd(dqzslzhzoh): HR = 0.61 (95% CI, 0.43 - 0.86), P-Value = 0.004 View more	Positive	01 Sep 2024
				Clopidogrel
ESC2024	Not Applicable	-	-	Clopidogrel monotherapy	fndasvkokz(poelclqplv) = xolpstrazl mtrjfoebsm (gbetqgjzle ) View more	-	30 Aug 2024
				Aspirin monotherapy	fndasvkokz(poelclqplv) = yuwdpgolsq mtrjfoebsm (gbetqgjzle ) View more
NCT03161678 (CTgov)	Phase 4	Thrombosis \| Myocardial Infarction \| Blood Platelet Disorders	111	Clopidogrel+Ticagrelor (Wild-Type Genotype)	yuvyfnraoy(epdlfnrhta) = zfnzkcsoyl hrvadjbsdk (bxqlkkjbhl, 2.7) View more	-	06 May 2024
				Clopidogrel+Ticagrelor (Carriers of the CES1 G143E Mutation)	yuvyfnraoy(epdlfnrhta) = phseodzvzz hrvadjbsdk (bxqlkkjbhl, 2.1) View more
NCT04409834 (COVID-PACT, CTgov)	Phase 4	COVID-19 \| Arterial thrombosis \| Venous Thromboembolism	390	Unfractionated Heparin IV+Clopidogrel+Enoxaparin 1 mg/kg (Full-dose Anticoagulation (FDAC))	vpbpozxphx(nbuxfpqpub) = vzsvmtuwpo hbhkbxcnyh (molkrjhetx, yeitfjbdiv - oiagrhehux) View more	-	19 Jan 2024
				Unfractionated heparin SC+Clopidogrel+Enoxaparin 40 mg SC (Standard-dose Prophylactic Anticoagulation (SDPAC))	vpbpozxphx(nbuxfpqpub) = gqqhduisqr hbhkbxcnyh (molkrjhetx, cgvqcfwnxz - trbxzhywct) View more
NCT03774394 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Coronary Artery Disease \| Chronic Kidney Diseases	61	Clopidogrel (Diabetes Mellitus Patients With Chronic Kidney Disease)	fjnxzwdobd(uhnprecvsf) = gzlabhbeyr chubkaiyen (siutcuvmzw, 27.4) View more	-	21 Aug 2023
				Clopidogrel (Diabetes Mellitus Patients Without Chronic Kidney Disease)	fjnxzwdobd(uhnprecvsf) = dccbqvcwgx chubkaiyen (siutcuvmzw, 30.2) View more
NCT03188705 (CTgov)	Phase 4	Thrombosis \| Occlusion of artery \| Coronary Artery Disease ... View more	6	Clopidogrel+Aspirin (Clopidogrel Alone Followed by Clopidogrel and Aspirin Treatment)	prbcbiljcz(kiaeueoein) = zdgrkhgqcm qhmcvdipup (ukztabjtbg, 5.5) View more	-	15 Jun 2023
				Clopidogrel (Clopidogrel Alone Treatment)	bgebhhebvo(frodsbpxwb) = kfyxeyvkvc vjnvlwixwn (upqvfrvich, ojmkrzmwud - qhahijlrrs) View more
NCT00979589 (CHANCE, Pubmed \| Stroke)	Phase 3	Stroke \| Ischemic Attack, Transient	2,853	Aspirin plus Clopidogrel	gphfddhvuq(iyevbxkofa) = dczsgpukxh ouearzeqsd (jjtpavmfrc ) View more	-	02 Jun 2023
				Aspirin alone	gphfddhvuq(iyevbxkofa) = mlxnhhxwuf ouearzeqsd (jjtpavmfrc ) View more